William Shakespeare - 06 Nov 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.

Reporting relationship: President of Research and Development
Issuer ticker: N/A
Reported as of: 06 Nov 2023
Net transaction value: +$80,347
SEC form: 4
Accepted by SEC: 07 Nov 2023, 16:03:37 UTC
Prior SEC filing: 02 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Bradford Dahms - Attorney-in-Fact

Key filing fact

William Shakespeare filed Form 4 for Theseus Pharmaceuticals, Inc. on 07 Nov 2023.

Key facts

This page summarizes William Shakespeare's Form 4 filing for Theseus Pharmaceuticals, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Nov 2023, 16:03.

Change

Previous filing in this sequence was filed on 02 Mar 2023.
Current net transaction value: +$80,347.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

THRX transaction

Common Stock

Options Exercise

Transaction value: $80,347
Shares: +251,084
Change %: +65%
Price: $0.3200^*
Shares after: 639,408
Date: 06 Nov 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

THRX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -251,084
Change %: -73%
Price: $0.000000
Shares after: 93,260
Date: 06 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 251,084
Exercise price: $0.3200
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer.

SEC remarks

President of Research and Development